Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are:
To correlate pharmacokinetic parameters of raltegravir and midazolam with irinotecan (CPT-11)
and its metabolite SN-38.
To correlate the genotype of UGT1A1 of patients receiving CPT-11 chemotherapy with irinotecan
and raltegravir pharmacokinetic parameters.
To model pharmacokinetic and pharmacodynamic behaviour of CPT-11 in the study population.